VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
10.12.2024 07:30:00 CET | ACCESS Newswire | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals
KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.
RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico.
"RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.
Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide."
"VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.
Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."
In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.
About VisiRose
VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.
About Bascom Palmer Eye Institute
The Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:
Clinical development programs in oncology, dermatology, and ophthalmology,
In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.
Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.
For Media Inquiries:
VisiRose, Inc.
E: contact@visirose.com
W: visirose.com
Contact:
VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
E: rodrigues@visirose.com
SOURCE: VisiRose
View the original press release on accesswire.com
VisiRose
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B23.2.2026 13:10:00 CET | Press release
Industry Leading UAS Expands Mission Roles To Include Naval Strike SAN DIEGO, CA / ACCESS Newswire / February 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is developing the addition of long-range standoff weapons to its top-of-the-line MQ-9B SkyGuardian® and SeaGuardian®. Demand continues from naval and air warfighters for platforms that can hold targets at risk from great ranges, especially over the expanses of air and water in the Western Pacific. That's why GA-ASI engineers have begun the work of adapting MQ-9B's payload, stability, range and other features to accommodate the new generation of extended-range precision weapons. "MQ-9B continues to impress in the field and we keep adding to our global customer list," said GA-ASI President David R. Alexander. "We want to continue to build value in the aircraft by expanding into more missions. MQ-9B features extraordinary payload capacity, so it only makes sense to add to our mission sets with the ability to carry long
GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise23.2.2026 13:05:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / In collaboration with the U.S. Air Force, General Atomics Aeronautical Systems, Inc. (GA-ASI) conducted its latest demonstration performing an autonomous mission out of Edwards Air Force Base in Southern California using its MQ-20 Avenger® unmanned jet and an F-22 Raptor equipped with the latest government reference autonomy software. The test, which showcased Manned-Unmanned Teaming between the F-22 and MQ-20, leveraged autonomy and the tactical data link to enable coordination between the platforms. The mission included a live engagement between the MQ-20 and the F-22 as the command aircraft flown by an onboard human pilot, highlighting the ability to receive and execute teaming commands. "We appreciate the flawless execution of this mission using the government's advanced autonomous systems," said GA-ASI President David R. Alexander. "This demo featured the integration of mission elements and the ability of autonomy to ut
GA-ASI Announces YFQ-42A Dark Merlin23.2.2026 13:00:00 CET | Press release
Uncrewed Fighter Jet Takes Inspiration From Nimble Predator SAN DIEGO, CA / ACCESS Newswire / February 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is giving its U.S. Air Force Collaborative Combat Aircraft a new name: YFQ-42A Dark Merlin. Dark merlins, deadly falcons known for their black feathers and devouring of other falcons as prey, often collaborate in groups for maximum effect against their targets. The Cornell Lab of Ornithology describes the merlin as a "small, fierce falcon that uses surprise attacks" to bring down its prey in flight. The dark merlin is native to the Pacific Northwest of the United States, often migrating into southern California, where bird spotters routinely report seeing them near the YFQ-42A's manufacturing home in San Diego. The 1962 book "Profiles of the Future" imagined global technological marvels yet to change the world, offering that "any sufficiently advanced technology is indistinguishable from magic." It's no coincidence that th
Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange20.2.2026 14:08:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / February 20, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies announced today the anticipated launch of the Josh Gibson Stablecoin and dedicated Josh Gibson Name, Image, and Likeness (NIL) strategies for its forthcoming sports and entertainment focused NIL digital asset exchange. This initiative builds directly on Major League Baseball's (MLB's) historic integration of Negro Leagues (1920-1948) statistics into the official major league record and celebrates Black History Month by honoring the legacy of baseball icon Josh Gibson. As outlined in the MLB's May 2024 press release, the statistics of the Negro Leagues have officially entered the major league record, recognizing the achievements of thousands of black players previously excluded from MLB. Josh Gibson, widely regarded as one of the greatest catchers a
Masterminds Education Named "Most Nurturing Early Education Environment" at UAE Business Awards 2026; Standardizes Early Learning Model with 12-Student Class Cap Structured as Two Learning Groups of Six20.2.2026 08:35:00 CET | Press release
Dubai-based provider marks 10 consecutive years of recognition and reinforces a whole-child program delivered through ultra-small learning groups DUBAI, AE / ACCESS Newswire / February 20, 2026 / Masterminds Education announced today that it has been recognized at the UAE Business Awards 2026 with two honors: Most Nurturing Early Education Environment 2026 and Child Development Excellence Award 2026. The awards extend Masterminds' record of 10 consecutive years of recognition and reinforce the organization's focus on high-impact early education built on consistency, relationships, and outcomes. As part of strengthening the operating conditions behind the "Most Nurturing" recognition, Masterminds Early Learning Center in Dubai announced an optimization to its early education structure: beginning in the 2026-27 academic year, the Early Learning Center will operate with a maximum class size of 12 students across Preschool through KG2, organized as two learning groups of six within each cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom